SPECTAZOLE
LOE ApproachingNDATOPICALCREAM
Approved
Dec 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPECTAZOLE is a topical cream small-molecule antifungal approved in 1982 for dermatological fungal infections. The active ingredient and specific mechanism of action are not publicly detailed in available data. Patients apply this cream directly to affected skin areas for localized antifungal treatment.
LOE Approaching
As LOE approaches, brand teams should expect declining headcount and budget reallocation toward pipeline assets or cost-optimization roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SPECTAZOLE offers limited growth opportunity given its LOE-approaching lifecycle, but provides stable experience in mature brand management, field execution, and regulatory compliance. Roles on this product are well-suited for professionals seeking operational mastery rather than launch excitement or pipeline innovation.
Brand ManagerField Sales Representative
Worked on SPECTAZOLE at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.